2 most recent filings and news items mentioning ABUS. Updated every 60 seconds.
LegalJul 16, 2026Positive
Genevant will pay Arbutus a $1 million termination fee following the termination of the mRESVIA Agreement as part of the broader patent settlement with Moderna. This action clarifies recovery rights and finalizes terms under the new settlement.
View filing at SEC.gov →
OtherMay 27, 2026Neutral
Arbutus Biopharma established a new equity compensation plan enabling grants of stock options, RSUs, and other awards to employees and key personnel. The plan is designed to align employee incentives with shareholder value creation and support long-term talent retention.
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.